Suven Life Sciences is currently trading at Rs. 328.00, up by 10.25 points or 3.23% from its previous closing of Rs. 317.75 on the BSE.
The scrip opened at Rs. 319.00 and has touched a high and low of Rs. 328.60 and Rs. 317.25 respectively. So far 100578 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 334.90 on 09-Apr-2015 and a 52 week low of Rs. 74.10 on 17-Apr-2014.
Last one week high and low of the scrip stood at Rs. 334.90 and Rs. 288.30 respectively. The current market cap of the company is Rs. 4048.22 crore.
The promoters holding in the company stood at 59.44% while Institutions and Non-Institutions held 9.22% and 31.34% respectively.
Suven Life Sciences has completed the single ascending dose (SAD) studies of SUVN-G3031 in healthy human volunteers and initiated multiple ascending dose studies (MAD) as a part of the Phase I study currently ongoing in USA under US-IND 123179. SUVN-G3031 is a potent, selective, brain penetrant and orally active Histamine H3 inverse agonist being developed for the treatment of cognitive dysfunction associated with Alzheimer’s disease and Schizophrenia.
The Phase-1 study was designed to evaluate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy volunteers. The tolerability of SUVN-G3031 up to the highest dose administered in SAD study is excellent. No serious adverse events occurred. SUVN-G3031 demonstrated excellent pharmacokinetics with a potential for once in a day dosing.
Histaminergic dysfunction has been strongly associated with the cognitive and behavioral deficits observed in several CNS disorders. Hence novel, potent, selective, brain penetrant and orally active H3 receptor inverse agonist for the treatment of cognitive deficits would offer new line of treatment for the unmet medical needs in Alzheimer’s disease, Schizophrenia and other CNS disorders.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. The company has 11 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and obesity in addition to Phase 2 ready developmental candidate SUVN-502 for and Phase1 candidate SUVNG3031 for Alzheimer’s disease and Schizophrenia.
